No profile data available.
Vistagen Therapeutics, Inc. (VTGN) is a healthcare company in the brain and nerve treatment drugs industry, based in South San Francisco, United States, with about 41 full-time employees.
It reported revenue of $1.27 million for fiscal year 2026, up 161.1% from fiscal year 2025, and net income of -$69.69 million. In Q1 2027 (the quarter ended June 30, 2026) revenue was $1.48 million, up 504.9% from a year before. Its market capitalization was $10.48 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2026; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
Vistagen Therapeutics reported $1.27 million in revenue for fiscal year 2026, up 161.1% from $486,000 in fiscal year 2025. In Q1 2027 revenue was $1.48 million.
$10.48 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include BioVie Inc. (BIVI), Passage Bio, Inc. (PASG), Brainstorm Cell Therapeutics Inc. (BCLI), Aeon Biopharma, Inc. (AEON).